Adaptive Biotechnologies Corp vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.91 (market cap $4.04B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SGOV | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $100.74 |
52-Week Low | $12.30 | $100.28 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.515 with minimal daily movement (+0.01%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators are neutral. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced exposure. The fund provides exposure to ultra-short-term Treasury bonds with monthly distributions, currently yielding approximately 3.8%.
SGOV serves as a defensive cash alternative amid market volatility, offering principal protection and minimal interest rate risk. The fund benefits from rising benchmark rates but faces pressure from potential Fed rate hikes and inflation concerns. Current macro uncertainty and steepened yield curve create both opportunity and risk for Treasury-focused investors.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →